133258-40-9

Upstream product

• 114433-94-2 1-(4-Fluorophenyl)-3-isopropylpropan-1,3-dione 
• 54608-52-5 2-hydrazinylpyrazine 

Downstream Products

• 786611-53-8 (E)-(3R,5S)-7-[5-(4-Fluoro-phenyl)-3-isopropyl-1-pyrazin-2-yl-1H-pyrazol-4-yl]-3,5-dihydroxy-hept-6-enoic acid 
• 133258-45-4 trans-7-[5-(4-Fluorophenyl)-3-(1-methylethyl)-1-(2-pyrazinyl)-1H-pyrazol-4-yl]-5-hydroxy-3-oxo-6-heptenoic acid, ethyl ester 
• 133258-42-1 (E)-3-[5-(4-Fluoro-phenyl)-3-isopropyl-1-pyrazin-2-yl-1H-pyrazol-4-yl]-acrylic acid ethyl ester 
• 133258-43-2 trans-3-[5-(4-Fluorophenyl)-3-(1-methylethyl)-1-(2-pyrazinyl)-1H-pyrazol-4-yl]2-propen-1-ol 
• 133258-44-3 trans-3-[5-(4-Fluorophenyl)-3-(1-methylethyl)-1-(2-pyrazinyl)-1H-pyrazol-4-yl]-2-propenal 
• 133258-41-0 2-[4-bromo-5-(4-Fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-1-yl]pyrazine 

Relevant academic research and scientific papers

Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5- disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones

A series of N-heteroaryl-substituted mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and in vivo, and to lower plasma cholesterol in a hypercholesterolemic dog model. The goal of the str

Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis

Certain trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)ethyl]- or ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones and the corresponding ring-opened acids, esters and N-oxides derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-m